CLINICAL TRIALS PROFILE FOR POTIGA
✉ Email this page to a colleague
All Clinical Trials for POTIGA
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02149836 ↗ | Study to Treat Major Depressive Disorder (MDD) With a New Medication | Completed | Icahn School of Medicine at Mount Sinai | Phase 2 | 2014-08-01 | The purpose of this study is to test the antidepressant effects of Ezogabine in major depressive disorder (MDD). The investigators also aim to determine the safety and tolerability Ezogabine in patients with MDD. The investigators hypothesize that depressive symptoms will be significantly decreased following an 8-week treatment period of the medication compared to baseline. |
NCT02450552 ↗ | Clinical Trial of Ezogabine (Retigabine) in ALS Subjects | Completed | ALS Association | Phase 2 | 2015-06-01 | This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks. |
NCT02450552 ↗ | Clinical Trial of Ezogabine (Retigabine) in ALS Subjects | Completed | GlaxoSmithKline | Phase 2 | 2015-06-01 | This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks. |
NCT02450552 ↗ | Clinical Trial of Ezogabine (Retigabine) in ALS Subjects | Completed | Harvard University | Phase 2 | 2015-06-01 | This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks. |
NCT02450552 ↗ | Clinical Trial of Ezogabine (Retigabine) in ALS Subjects | Completed | Massachusetts General Hospital | Phase 2 | 2015-06-01 | This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks. |
NCT02450552 ↗ | Clinical Trial of Ezogabine (Retigabine) in ALS Subjects | Completed | Brian Wainger | Phase 2 | 2015-06-01 | This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for POTIGA
Condition Name
Clinical Trial Locations for POTIGA
Trials by Country
Clinical Trial Progress for POTIGA
Clinical Trial Phase
Clinical Trial Sponsors for POTIGA
Sponsor Name